Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.43+0.39 (+3.53%)
Close on Nov 18, 2026Market cap $5.59BP/E –Yield –
Gossamer Bio total assets
Total assets on the balance sheet at the end of each period.
Gossamer Bio's total assets was $76.87M at Jun 30, 2026. For fiscal 2025 it was $172.25M, down 45.4% from the year before. The highest annual figure on record is $539.43M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.25M | -45.4% |
| FY2024 | Dec 31, 2024 | $315.29M | +1.1% |
| FY2023 | Dec 31, 2023 | $311.92M | +14.5% |
| FY2022 | Dec 31, 2022 | $272.45M | -20.7% |
| FY2021 | Dec 31, 2021 | $343.66M | -36.3% |
| FY2020 | Dec 31, 2020 | $539.43M | +26.4% |
| FY2019 | Dec 31, 2019 | $426.60M | +78.2% |
| FY2018 | Dec 31, 2018 | $239.42M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $76.87M | -68.1% |
| Q1 FY2026 | Mar 31, 2026 | $128.90M | -54.1% |
| Q4 FY2025 | Dec 31, 2025 | $172.25M | -45.4% |
| Q3 FY2025 | Sep 30, 2025 | $208.82M | -40.5% |
| Q2 FY2025 | Jun 30, 2025 | $240.93M | -35.5% |
| Q1 FY2025 | Mar 31, 2025 | $280.59M | +8.2% |
| Q4 FY2024 | Dec 31, 2024 | $315.29M | +1.1% |
| Q3 FY2024 | Sep 30, 2024 | $350.88M | +0.8% |
| Q2 FY2024 | Jun 30, 2024 | $373.45M | +105.5% |
| Q1 FY2024 | Mar 31, 2024 | $259.36M | +17.9% |
| Q4 FY2023 | Dec 31, 2023 | $311.92M | +14.5% |
| Q3 FY2023 | Sep 30, 2023 | $347.93M | +7.5% |
| Q2 FY2023 | Jun 30, 2023 | $181.75M | -26.1% |
| Q1 FY2023 | Mar 31, 2023 | $219.91M | -25.4% |
| Q4 FY2022 | Dec 31, 2022 | $272.45M | -20.7% |
| Q3 FY2022 | Sep 30, 2022 | $323.54M | -16.4% |
| Q2 FY2022 | Jun 30, 2022 | $245.84M | -43.2% |
| Q1 FY2022 | Mar 31, 2022 | $294.68M | -38.9% |
| Q4 FY2021 | Dec 31, 2021 | $343.66M | -36.3% |
| Q3 FY2021 | Sep 30, 2021 | $387.04M | -33.7% |
| Q2 FY2021 | Jun 30, 2021 | $432.51M | -30.8% |
| Q1 FY2021 | Mar 31, 2021 | $482.47M | +29.9% |
| Q4 FY2020 | Dec 31, 2020 | $539.43M | +26.4% |
| Q3 FY2020 | Sep 30, 2020 | $584.18M | +24.4% |
| Q2 FY2020 | Jun 30, 2020 | $625.08M | +23.2% |
| Q1 FY2020 | Mar 31, 2020 | $371.48M | -28.0% |
| Q4 FY2019 | Dec 31, 2019 | $426.60M | +78.2% |
| Q3 FY2019 | Sep 30, 2019 | $469.75M | – |
| Q2 FY2019 | Jun 30, 2019 | $507.17M | – |
| Q1 FY2019 | Mar 31, 2019 | $515.95M | – |
| Q4 FY2018 | Dec 31, 2018 | $239.42M | – |
See a number that looks wrong?